What Is The Current and Historic Market Size Analysis Of The Rheumatology Therapeutics Market?
The rheumatology therapeutics market has seen considerable growth due to a variety of factors.
• The rheumatology therapeutics market has expanded strongly in recent years. It will increase from $42.4 billion in 2024 to $44.61 billion in 2025, at a compound annual growth rate (CAGR) of 5.2%.
The growth has been fueled by the rising prevalence of rheumatologic disorders, an aging global population, and advancements in biological therapies.
What Are The Predictions for The Rheumatology Therapeutics Market in the Coming Years?
The rheumatology therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• The rheumatology therapeutics market is expected to reach $53.88 billion by 2029, growing at a CAGR of 4.8%.
Growth drivers include personalized medicine, the adoption of biosimilars, increased research and development, the integration of digital health technologies, and regulatory approvals for new therapies. Trends include growth in telemedicine and remote monitoring, expansion of targeted therapies, patient-centric care models, biologic treatments, and value-based pricing.
Which Drivers Are Accelerating Growth In The Rheumatology Therapeutics Market?
The escalation in the frequency of autoimmune diseases is anticipated to accelerate the expansion of the rheumatology therapeutics market in the future. Autoimmune diseases arise when the immune system erroneously harms the body's own tissues. This mounting occurrence is due to an amalgamation of genetic, environmental, and lifestyle influences, coupled with heightened awareness and advanced diagnostic capabilities. There is a need for rheumatology therapeutics to control inflammation, relieve symptoms and stave off damage to joints and tissues caused by the immune system's assault on the body in autoimmune diseases. For example, the Australian Institute of Health and Welfare, a government agency based in Australia, revealed in June 2024 that approximately 514,000 inhabitants of Australia, translating to 2.0% of the population, were thought to be suffering from rheumatoid arthritis back in 2022. The burden of this ailment represented 2.0% of the total disease load and 16% of the burden from all musculoskeletal disorders in 2023. Hence, the upward trend in the incidence of autoimmune diseases is fuelling the surge of the rheumatology therapeutics market.
What Are The Core Segments Of The Global Rheumatology Therapeutics Market?
The rheumatology therapeutics market covered in this report is segmented –
1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications
Subsegments:
1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs
2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors, Traditional NSAIDs
3) By Corticosteroids: Oral Corticosteroids, Injectable Corticosteroids, Topical Corticosteroids
4) By Uric Acid Drugs: Uric Acid Lowering Agents, Uricosuric Agents, Pegloticase
5) By Other Drug Classes: Immunosuppressants, Biologic Therapies, Analgesics
Pre-Book The Rheumatology Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Rheumatology Therapeutics Market?
Leading firms in the rheumatology therapeutics market are transforming therapy effectiveness and patient comfort by introducing novel solutions like intravenous (IV) formulations. IV formulations are medications or substances directly applied into a vein using a needle or a catheter. For instance, a development in October 2023 by the Swiss pharmaceutical firm Novartis AG saw the US Food and Drug Administration (FDA) approval of Cosentyx, an IV formulation. This version of Cosentyx received exclusive endorsement for use in adults suffering from psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). It operates by selectively inhibiting interleukin-17A (IL-17A) and remains the only non-tumor necrosis factor alpha (TNF-a) IV therapy for these disorders.
Who Are the Key Players In The Rheumatology Therapeutics Market?
Major companies operating in the rheumatology therapeutics market are:
• Pfizer Inc.
• Johnson & Johnson
• Roche Holding AG
• Merck & Co. Inc.
• AbbVie Inc.
• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Gilead Sciences Inc.
• Janssen Biotech
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Vertex Pharmaceuticals
• UCB S.A.
• Galapagos NV (GLPG)
• Genentech Inc.
What Are The Regional Insights Into The Rheumatology Therapeutics Market?
North America was the largest region in the rheumatology therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
